<p>In contrast to <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001625#pntd-0001625-g006" target="_blank">Figure 6</a>, a plot of potency against <i>Ldon</i> and <i>Hs</i>1 NMTs showed that activity did not correlate. Excellent selectivity was observed for several chemical series. The structures of representative members of four series are given in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001625#pntd-0001625-g005" target="_blank">Figure 5</a>.</p
1<p>Reviewed in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0000659#pntd....
<p>(A) Percent inhibition of NDM-1 activity in the presence of 30 uM individual compounds. Data are ...
<p>Of fifteen compounds surviving dose-response potency testing, five commercially-available molecul...
<p>Triage of the primary screening hits made use of local hit rate analysis; ligand efficiency again...
<p>Compounds with >40% activity against either <i>Ldon</i> [red], <i>Pfal</i> [yellow] or both NMT t...
<p># Hits are compounds in series with activity <5 µM against the respective NMT. LHR = Local hit ra...
<p>Comparison of IC<sub>50</sub>s for compounds inhibiting cAMP generation via Hs.5HT7R (abscissa) o...
1<p>Ref 35.</p>2<p>structures shown in <a href="http://www.plosntds.org/article/info:doi/10.1371/jou...
<p>(a) Summary scatter plot. Positions along axes report the median binding affinity of all compound...
The triage of compounds at the single-concentration screening phase of high-throughput screening (HT...
<p>All data are in µM. <i>Pfal</i> and <i>Ldon</i> NMT values are the mean of 3 determinations, <i>H...
<p>Histogram distributions of cLogP, MW and TPSA for (a) the whole HTS set (42,444 compounds, red), ...
<p>Plots of HOMO and LUMO of most active compound 1 along with potent hits KM09155, HTS00581, HTS058...
<p>A. Distribution of active compounds in the WT (blue) and N370S/N370S spleen (red) HTS experiments...
<p>Hit compounds of the primary screen were retested in replicates at 3 and 10 µM against HMGB1 and ...
1<p>Reviewed in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0000659#pntd....
<p>(A) Percent inhibition of NDM-1 activity in the presence of 30 uM individual compounds. Data are ...
<p>Of fifteen compounds surviving dose-response potency testing, five commercially-available molecul...
<p>Triage of the primary screening hits made use of local hit rate analysis; ligand efficiency again...
<p>Compounds with >40% activity against either <i>Ldon</i> [red], <i>Pfal</i> [yellow] or both NMT t...
<p># Hits are compounds in series with activity <5 µM against the respective NMT. LHR = Local hit ra...
<p>Comparison of IC<sub>50</sub>s for compounds inhibiting cAMP generation via Hs.5HT7R (abscissa) o...
1<p>Ref 35.</p>2<p>structures shown in <a href="http://www.plosntds.org/article/info:doi/10.1371/jou...
<p>(a) Summary scatter plot. Positions along axes report the median binding affinity of all compound...
The triage of compounds at the single-concentration screening phase of high-throughput screening (HT...
<p>All data are in µM. <i>Pfal</i> and <i>Ldon</i> NMT values are the mean of 3 determinations, <i>H...
<p>Histogram distributions of cLogP, MW and TPSA for (a) the whole HTS set (42,444 compounds, red), ...
<p>Plots of HOMO and LUMO of most active compound 1 along with potent hits KM09155, HTS00581, HTS058...
<p>A. Distribution of active compounds in the WT (blue) and N370S/N370S spleen (red) HTS experiments...
<p>Hit compounds of the primary screen were retested in replicates at 3 and 10 µM against HMGB1 and ...
1<p>Reviewed in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0000659#pntd....
<p>(A) Percent inhibition of NDM-1 activity in the presence of 30 uM individual compounds. Data are ...
<p>Of fifteen compounds surviving dose-response potency testing, five commercially-available molecul...